Phillips-Medisize Wins Contract to Manufacture First Electronic-Enabled Combination Drug Delivery Product
22.10.2019 18:30:00 EEST | Business Wire | Press release
Phillips-Medisize, a Molex company, announced today an agreement with a leading biotechnology company to manufacture a wearable, electronic-enabled combination product. The product is a post-phase III development-stage combination drug and device that combines two-day, single use, disposable technology for subcutaneous drug delivery.
The wearable combination product – which is replaced every two days – is about the size of a hockey puck, and can either be adhered to the patient’s body, via an adhesive patch, or worn near the infusion site.
Phillips-Medisize, which built devices and supplied key data to support the FDA NDA submission, will provide final assembly, testing and quality control of this electronic combination product. Specifically, Phillips-Medisize will handle the prefilled drug cartridge that fits inside the device. This drug container is aseptically filled and shipped to Phillips-Medisize. Several state-of-the-art Phillips-Medisize facilities are involved in various stages of manufacturing the combination product – including molding, assembly, drug handling, labeling, reconciliation and more.
“This exciting new contract taps over 13 years of Phillips-Medisize’s combination product expertise, which includes cold chain drug handling and first programs with API handling. We have experience in manufacturing both combination and electronic-enabled drug delivery devices, and this is our first product submitted for FDA approval that includes both,” said Matt Jennings, CEO and President, Phillips-Medisize.
Pending receipt of FDA approval, Phillips-Medisize is contracted to provide commercialization services from its Hudson, WI-based manufacturing site. The combination product is slated for launch in 2H 2020. Backed by Phillips-Medisize’s scalability to move to high volume production, the product will be well positioned for a successful market launch.
Strong potential also exists to bring the device onto a connected health platform in the future, by embedding low-cost connectivity that will make it possible to capture and communicate data between patient and provider in order to help monitor adherence.
About Phillips-Medisize
Phillips-Medisize, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, medical device and specialty commercial market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com or www.molex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005826/en/
Contact information
For more information, contact:
Heather Ditzler
Phone +1 715-377-7261
heather.ditzler@phillipsmedisize.com
Paula Kasper (Europe)
Phone +41448383933
paula.kasper@phillipsmedisize.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Schneider Electric Concludes Innovation Summit Middle East & Africa, Highlights Energy Intelligence as the Next Phase of the Energy Transition16.9.2026 16:30:00 EEST | Press release
As AI, electrification and industrial expansion reshape energy demand across the Middle East and Africa, Schneider Electric today concluded Innovation Summit Middle East & Africa by positioning energy intelligence as the next phase of the energy transition - where infrastructure becomes more connected, resilient and software-defined. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916593883/en/ Walid Sheta, President, MEA Zone at Schneider Electric, releasing the company's 2026 Industrial AI in CPG Study for the UAE, at Schneider Electric Innovation Summit MEA (Photo: AETOSWire) Held at ADNEC in Abu Dhabi, the two-day summit convened over 2,500 attendees, including government leaders, industry analysts, customers, partners, students, and media, under the theme ‘Advancing Energy Tech to Power Intelligence and Resilience.’ Industry leaders explored how electrification, AI-ready data centers, cybersecurity, and digital innova
The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision16.9.2026 15:23:00 EEST | Press release
Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916231950/en/ Outdoor relaxation area at Jayasom Wellness Resort AMAALA, where serene design and sea-facing spaces create a setting for rest and renewal. Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal. “As we launch the first Jayasom globally, we are bringing a new dimension to AMAALA’s wellness offering. Its dedicated, all-inclusive wellness retreats combine contemporary, evidence-based practices with Arab and East
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth16.9.2026 15:01:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916811892/en/ Figure Legend: Representative images of intact ex vivo human hair follicles challenged with DHT 100 nM and stimulated with finasteride 600 nM (positive control) or RLS-1496 2000 nM at Days 0 and 6. RLS-1496 has already demonstrated efficacy in clinical trials for actinic keratoses and aging skin, and other skin conditions such as psoriasis and atopic dermatitis, generating novel human evidence demonstrating the dual SenoAdaptive mec
NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence16.9.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond. “NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infrastructure will help us deliver a more seamless and connected experience for our Krewe at games and across the digital platforms that we use.” T
Unique Australian Clay: Multi Minerals Australia’s Non-antibiotic Solution for Poultry Production16.9.2026 14:44:00 EEST | Press release
Multi Minerals Australia, a leading mining company, announced a one-of-a-kind formulation of Australian clays which has proven it can reshape the global poultry feed economic landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916711777/en/ Unique, non-antibiotic clay stockfeed component and production enhancer from Multi Minerals Australia. Sourced from its one-of-a-kind geological deposit. Proven results. Worldwide distribution. Potential applications and lower cost benefits to a range of commercial animal production, particularly poultry. Expressions of interest sought. Numerous scientific, clinical, and commercial producer validations have demonstrated the product’s significant benefits; including the reduction of feed costs; improvements in: growth; meat yield; feed conversion; resistance to heat stress; eggshell quality and production: reduced inflammation and mortality in layer and broiler production. It has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom